Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.

[1]  N. Heddle,et al.  An evaluation of methods for determining reference intervals for light transmission platelet aggregation tests on samples with normal or reduced platelet counts , 2008, Thrombosis and Haemostasis.

[2]  G. Lip,et al.  The role of aspirin in cardiovascular prevention: implications of aspirin resistance. , 2008, Journal of the American College of Cardiology.

[3]  P. Barragan,et al.  Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. , 2008, Journal of the American College of Cardiology.

[4]  S. Brister,et al.  Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis , 2008, BMJ : British Medical Journal.

[5]  J. Jukema,et al.  Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. , 2007, American heart journal.

[6]  C. Macaya,et al.  Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. , 2007, Journal of the American College of Cardiology.

[7]  D. Angiolillo,et al.  Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study , 2007, Circulation.

[8]  C. Cerletti,et al.  Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor , 2006, Thrombosis and Haemostasis.

[9]  J. Suh,et al.  Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel , 2006, Canadian Medical Association Journal.

[10]  W. Weaver,et al.  Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. , 2006, American heart journal.

[11]  A. Kastrati,et al.  Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial , 2005, Circulation.

[12]  F. Neumann,et al.  Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention , 2005, Circulation.

[13]  W. Herzog,et al.  The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. , 2005, Journal of the American College of Cardiology.

[14]  J. Diodati,et al.  Resistance to clopidogrel: a review of the evidence. , 2005, Journal of the American College of Cardiology.

[15]  Deepak L. Bhatt,et al.  Variability in platelet responsiveness to clopidogrel among 544 individuals. , 2005, Journal of the American College of Cardiology.

[16]  C. Gachet,et al.  Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases , 2005, Journal of thrombosis and haemostasis : JTH.

[17]  M. Cattaneo.  Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[18]  C. Macaya,et al.  High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. , 2004, European heart journal.

[19]  J. Heikkilä,et al.  Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. , 2004, European heart journal.

[20]  W. Weimar,et al.  Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus , 2003, Clinical pharmacology and therapeutics.

[21]  Kevin P. Bliden,et al.  Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.

[22]  J. Leathart,et al.  CYP3A5 phenotype-genotype correlations in a British population. , 2003, British journal of clinical pharmacology.

[23]  H. Vapaatalo,et al.  Single dose of acetylsalicylic acid prevents thromboxane release after tourniquet ischemia. , 2003, The Journal of trauma.

[24]  Paul B. Watkins,et al.  Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug–Drug Interaction , 2003, Circulation.

[25]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[26]  C. Foster,et al.  Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. , 2002, Blood.

[27]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[28]  R. Peto,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[29]  R. Wilcox,et al.  Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease , 2002, Platelets.

[30]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[31]  R. Wilcox,et al.  Open Multicentre Study of the P 2T Receptor Antagonist AR-C69931MX Assessing Safety, Tolerability and Activity in Patients with Acute Coronary Syndromes , 2001, Thrombosis and Haemostasis.

[32]  V. Fuster,et al.  Acute Antithrombotic Effect of a Front-Loaded Regimen of Clopidogrel in Patients With Atherosclerosis on Aspirin , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[33]  P. Siljander,et al.  Studies of adhesion-dependent platelet activation: distinct roles for different participating receptors can be dissociated by proteolysis of collagen. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[34]  U. Walter,et al.  Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[35]  M. Hadamitzky,et al.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. , 1996, The New England journal of medicine.

[36]  J. Herbert,et al.  The Antiaggregating Activity of Clopidogrel Is due to a Metabolic Activation by the Hepatic Cytochrome P450-1A , 1994, Thrombosis and Haemostasis.

[37]  K. Winters,et al.  A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. , 2007, American heart journal.

[38]  E. Trabetti,et al.  Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. , 2005, Thrombosis research.

[39]  J. Hauert,et al.  Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. , 1999, Seminars in thrombosis and hemostasis.

[40]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[41]  M. Koulu,et al.  Plasma 3,4-dihydroxyphenylglycol (DHPG) and 3-methoxy-4-hydroxyphenylglycol (MHPG) are insensitive indicators of alpha 2-adrenoceptor mediated regulation of norepinephrine release in healthy human volunteers. , 1991, Life sciences.

[42]  M. Eadie,et al.  A sensitive liquid chromatographic assay for plasma aspirin and salicylate concentrations after low doses of aspirin. , 1985, Therapeutic drug monitoring.